Scope
AAOS 2026 addresses symptomatic ankle osteoarthritis with a clear distinction between evidence-supported recommendations and options based mainly on expert consensus. The strongest conclusions concern injections that should not be used routinely. Most rehabilitation, analgesic and surgical choices require shared decisions because ankle-specific comparative evidence remains limited.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Explain the differing evidence for injections
- Do not use intra-articular hyaluronic acid alone for symptomatic ankle osteoarthritis: this is a strong recommendation against treatment. The guideline allows possible short-term pain and functional benefit when hyaluronic acid is combined with corticosteroid, rather than endorsing hyaluronic acid monotherapy. [1]
- The combination evidence compares hyaluronic acid plus corticosteroid with corticosteroid alone, not placebo. It therefore cannot establish the combination’s absolute efficacy. [1]
- Do not routinely offer intra-articular platelet-rich plasma for symptomatic ankle osteoarthritis; the recommendation against routine use has moderate strength. [1]
- Corticosteroid injection alone is a consensus option for short-term symptom relief. Its magnitude and duration of benefit are uncertain in ankle-specific controlled evidence, and it is not disease-modifying. Discuss flare, infection, systemic effects and concerns about repeated injections. [1]
- The workgroup finds no reliable evidence for intra-articular stem-cell therapy in symptomatic ankle osteoarthritis. This is a statement of insufficient evidence, not proof of established benefit. [1]
Use conservative options with realistic expectations
- For mild-to-moderate symptomatic disease in people seeking to avoid surgery, skilled physical therapy is a consensus option that may improve reported outcomes. Group education and exercise including a home programme may improve satisfaction and pain, but supporting evidence is low and the option has limited strength. [1]
- NSAIDs or acetaminophen may provide initial symptomatic relief when no medical contraindication exists; this is consensus-based. Consider gastrointestinal, renal and cardiovascular risks with NSAIDs and hepatic risk with acetaminophen. Topical NSAIDs may be preferable when systemic risk is high. [1]
- Prescription opioids should not be used to manage symptomatic ankle osteoarthritis according to the workgroup’s consensus opinion. [1]
- Durable medical equipment may improve patient-reported outcomes and alter the course of symptoms or the need for invasive treatment, but this is a consensus option with insufficient supporting evidence. [1]
- Weight reduction may improve reported outcomes and symptom progression in symptomatic ankle osteoarthritis. The recommendation is a consensus option rather than a proven ankle-specific effect size or a mandatory weight threshold. [1]
Discuss surgery after unsuccessful non-operative care
- For persistent symptomatic disease after non-operative care, people seeking joint preservation may consider arthroscopic debridement or periarticular realignment osteotomy. These consensus options may improve outcomes or delay joint-sacrificing procedures. [1]
- For end-stage disease after unsuccessful non-operative treatment, fusion or total ankle replacement can improve patient-reported outcomes. This is a consensus option, and the evidence does not establish one procedure as universally superior. [1]
- Postoperative physical therapy may improve function, motion, strength, gait and return to activity. It is a consensus option; the summary does not specify one universal rehabilitation schedule. [1]
- Perioperative tranexamic acid may reduce blood loss or complications during total ankle replacement or fusion for end-stage disease. AAOS presents this as a consensus option based on very-low-quality evidence, without establishing a universal dose. [1]
Limitations and use
- Most statements in this guideline are consensus options; possible symptom improvement must not be described as proven structural disease modification. The summary retains the strong/moderate distinctions for injection recommendations.
- This does not supply diagnostic criteria, medication or injection doses, patient-specific surgical eligibility, implant selection, perioperative anticoagulation, or a rehabilitation prescription.
- The opioid statement concerns symptomatic osteoarthritis management. It should not be expanded into a separate postoperative analgesia rule or a directive to abruptly stop an existing opioid.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Management of Ankle Osteoarthritis
Guideline recommendation text consulted
Publication details
- Issuing organisation
- AAOS
- Resource type
- Clinical practice guideline · House clinical summary
- Source setting
- United States
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.